Cyclica (acquired by Recursion, Nasdaq: RXRX)
Biotechnology ResearchOntario, Canada2-10 Employees
Cyclica has been acquired by Recursion! Please follow @Recursion on LinkedIn and @RecursionPharma on Twitter to receive updates on our next chapter.
Acquisition Boost Cyclica has recently been acquired by Recursion, a Nasdaq-listed company, indicating strong financial backing and strategic growth potential, which can facilitate larger partnerships and investment in innovative biotech solutions.
Innovative Platform The launch of Beacons for Brands and its integrated affiliate marketplace demonstrates a focus on content monetization and creator engagement, presenting opportunities to offer complementary marketing, analytics, or AI-driven solutions for brand expansion.
Recent Funding Having secured a $6 million seed round, Beacons AI is positioned for growth initiatives, making it a promising prospect for collaborations in AI-driven content optimization and creator monetization tools.
Market Positioning With a niche in AI-powered content creation and monetization tools targeting creators and brands, there is potential to develop tailored solutions that enhance user engagement and expand market reach within the competitive creator economy space.
Technology Stack Utilizing modern tech like PWA, Facebook integrations, and other digital tools indicates a focus on scalable, user-friendly platforms, allowing sales teams to align offerings with cutting-edge digital marketing and content solutions for clients.
Cyclica (acquired by Recursion, Nasdaq: RXRX) uses 8 technology products and services including Google Ads, Canny, Punycode, and more. Explore Cyclica (acquired by Recursion, Nasdaq: RXRX)'s tech stack below.
| Cyclica (acquired by Recursion, Nasdaq: RXRX) Email Formats | Percentage |
| First.Last@cyclicarx.com | 100% |
| First@beacons.ai | 85% |
| Last@beacons.ai | 14% |
| FirstL@beacons.ai | 1% |
Biotechnology ResearchOntario, Canada2-10 Employees
Cyclica has been acquired by Recursion! Please follow @Recursion on LinkedIn and @RecursionPharma on Twitter to receive updates on our next chapter.
Cyclica (acquired by Recursion, Nasdaq: RXRX)'s revenue is estimated to be in the range of $1M$10M
Cyclica (acquired by Recursion, Nasdaq: RXRX)'s revenue is estimated to be in the range of $1M$10M